Progyny CEO Peter Anevski sold $6.18 million in company stock, according to a filing disclosed this week. Executive chairman David Schlanger sold $5.88 million in a separate filing around the same time. Together the two disposals add up to just over $12 million from the two people who sit closest to the company's operating and strategic decisions.
A single insider sale rarely moves a stock. Two of the most senior people at a company selling in the same short window is a different signal, because it removes the explanation that one executive simply needed liquidity for a personal reason. It raises the question of whether something about the company's near-term outlook, rather than individual circumstance, is driving the timing.
Neither filing disclosed a 10b5-1 trading plan date or a stated reason for the sale, so it isn't yet clear whether these were pre-scheduled disposals set up months in advance or discretionary decisions made now. That distinction matters: a long-standing 10b5-1 plan would make the overlap coincidental rather than informative.
What's unresolved is whether Progyny's stock price or an upcoming catalyst explains the timing. The company has not issued a statement tied to the sales.